NCT07461545Recruiting
Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS
Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After Laparoscopic Splenectomy
Source: ClinicalTrials.gov · Last updated 31 Mar 2026
Brief summary (registry, in English)
The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 4 Mar 2026
- Start date
- 1 Apr 2026
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- Northern Jiangsu People's Hospital
- Diseases
- High blood pressure
- NCT number
- NCT07461545
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 1 Apr 2026 to the primary completion date, 30 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Hepatocellular carcinoma or any other malignancy.
- Hypercoagulable state other than the liver disease related.
- Portal hypertension bleeding .
- Recent peptic ulcer disease
- History of Hemorrhagic stroke
- Uncontrolled Hypertension
- Human immunodeficiency virus (HIV) infection
Lab values
- DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs.
Other
- Child - Pugh C
- Pregnancy.
Who the study is looking for
- A clinical, radiological, or histologic diagnosis of cirrhosis of any etiology.
- Splenomegaly with secondary hypersplenism.
- No evidence of portal vein thrombosis by ultrasound evaluation and angio-CT prior to surgery.
- Underwent laparoscopic splenectomy at our center.
- Orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily or a 100 mg aspirin tablet (Bayer, Leverkusen, Germany) once daily for 6 months from POD 3.
- subcutaneous injections of low molecular weight heparin sodium (CSBio, Hebei, China) were administered for 5 days from POD 3
- Oral dipyridamole (Henan Furen, Henan, China) at a dosage of 25 mg, administered three times daily for 3 months from POD 3.
- Had no imaging evidence (Doppler ultrasound or CT) of portal vein thrombosis during postoperative months 6 to 12.
- Developed portal vein thrombosis after 12 months post-surgery.
- Provided informed consent to participate in the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical Medical College Coordinator of this site? Confirm its status | Yangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.